A microemulsion co-loaded with Schizandrin A–docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance

Xiangyu Su1 Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, P.R. China,

Chanchan Gao1 Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, P.R. China,

Fangfang Shi1 Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, P.R. China,

Xiaoyao Feng1 Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, P.R. China,

Lin Liu1 Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, P.R. China,

Ding Qu2 Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, P.R. China, and ;3 Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, P.R. ChinaCorrespondence[email protected] [email protected]

Cailian Wang1 Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, P.R. China,

show all

A microemulsion co-loaded with Schizandrin A–docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A microemulsion co-loaded with Schizandrin A–docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date